Michael Catelani, President, COO, & CFO at Anixa Biosciences Inc (ANIX), bought 5,500 shares at $2.84 ($16K) on 2026-09-30, disclosed to the SEC on 2026-09-30.
Anixa Biosciences President and CFO Michael Catelani purchased 5,500 shares for $15,620, signaling confidence in the company's oncology pipeline and recent analyst upgrades. The trade comes as the stock trades near its 52-week low, potentially offering a value entry point.
The stock is down 15.48% over the last 30 days and is currently trading 47.95% below its 52-week high of $5.46, while sitting 19.83% above the 52-week low of $2.37.
1) Zacks upgraded ANIX to a Strong Buy on July 22, 2026, citing growing earnings optimism. 2) The company views 2026 as a 'pivotal year' for its breast cancer vaccine and CAR-T therapies, with a planned Phase II study.
The stock is currently trading at a forward P/E of -9.29, indicating the market expects continued losses, and short interest is low at 3.2% of the float.
Something here stands out, but not much.
| Filing → |
| ANIX | BUY | 2023-07-21 | $20K | — | Filing → |
| ANIX | BUY | 2022-04-22 | $15K | — | Filing → |
| ANIX | BUY | 2022-04-21 | $6K | — | Filing → |